At the RBC Global Healthcare Conference, held on 14-15 May, RBC’s Healthcare Desk Sector Strategist gauged biotech investor sentiment in an interview with Biotech TV.
The strategist, Chris McCarthy, says he is trying to figure out investment sentiment and positioning.
When asked about what he heard in the conference hallways, Chris said biotech investors are focused on the upcoming binary catalysts.
Chris McCarthy highlighted some companies that have upcoming data readouts.
He adds that with data readouts, the investors see outsized stock moves, and they should start focusing on these companies as the readouts approach, including:
- Agios Pharmaceuticals Inc (NASDAQ:AGIO): Two key milestones for 2024, including topline data from the Phase 3 ENERGIZE-T study of mitapivat in transfusion-dependent thalassemia in Q2 and filing for FDA approval of mitapivat in thalassemia by year-end.
- Earlier this year, Agios Pharmaceuticals said ...